Olav Dalgard

Image of Olav Dalgard
Norwegian version of this page
Username
Visiting address Sykehusveien 25 1474 Nordbyhagen
Postal address Akershus universitetssykehus 1478 Lørenskog

Publications

  • Chalabianloo, Fatemeh; Høiseth, Gudrun; Vold, Jørn Henrik; Johansson, Kjell Arne; Kringen, Marianne K. & Dalgard, Olav [Show all 12 contributors for this article] (2022). Impact of liver fibrosis and clinical characteristics on dose-adjusted serum methadone concentrations. Journal of Addictive Diseases. ISSN 1055-0887. p. 1–12. doi: 10.1080/10550887.2022.2057140.
  • Midgard, Håvard; Bjørnestad, Ronny; Egeland, Maren; Dahl, Eivin; Finbråten, Ane-Kristine & Kielland, Knut Boe [Show all 8 contributors for this article] (2022). Peer support in small towns: A decentralized mobile Hepatitis C virus clinic for people who inject drugs. Liver international (Print). ISSN 1478-3223. doi: 10.1111/liv.15266.
  • Busschots, Dana; Bielen, Rob; Koc, Özgür M.; Heyens, Leen; Verrando, Rita & de Galocsy, Chantal [Show all 11 contributors for this article] (2021). Hepatitis C reinfection in former and active injecting drug users in Belgium. Harm Reduction Journal. ISSN 1477-7517. 18(1), p. 1–7. doi: 10.1186/s12954-021-00552-x.
  • Cunningham, Evan B.; Hajarizadeh, Behzad; Amin, Janaki; Hellard, Margaret; Bruneau, Julie & Feld, Jordan J. [Show all 23 contributors for this article] (2021). Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs. Clinical Infectious Diseases. ISSN 1058-4838. 72(8), p. 1392–1400. doi: 10.1093/cid/ciaa253.
  • Kåsine, Trine; Riise, Anne Margarita Dyrhol; Barratt-Due, Andreas; Kildal, Anders Benjamin; Olsen, Inge Christoffer & Nezvalova-Henriksen, Katerina [Show all 39 contributors for this article] (2021). Neutrophil count predicts outcome in hospitalized COVID-19 patients. Results from the NOR-Solidarity trial. Journal of Internal Medicine. ISSN 0954-6820. 291(2), p. 241–243. doi: 10.1111/joim.13377.
  • Axfors, Cathrine; Schmitt, Andreas; Janiaud, Perrine; Hooft, Janneke; Abd-Elsalam, Sherief & Abdo, Ehab [Show all 50 contributors for this article] (2021). Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nature Communications. ISSN 2041-1723. 12. doi: 10.1038/s41467-021-22446-z. Full text in Research Archive
  • Gahrton, Caroline; Håkansson, Anders; Kåberg, Martin; Jerkeman, Anna; Häbel, Henrike & Dalgard, Olav [Show all 8 contributors for this article] (2021). Mortality among amphetamine users with hepatitis C virus infection: A nationwide study. PLOS ONE. ISSN 1932-6203. 16(6), p. 1–15. doi: 10.1371/journal.pone.0253710. Full text in Research Archive
  • Duffell, Erika; Cortez-Pinto, Helena; Simonova, Marieta; Dalgard, Olav; Dahl, Elin Hoffmann & de Martel, Catherine [Show all 13 contributors for this article] (2021). Estimating the attributable fraction of cirrhosis and hepatocellular carcinoma due to hepatitis B and C. Journal of Viral Hepatitis. ISSN 1352-0504. 28(8), p. 1177–1189. doi: 10.1111/jvh.13545.
  • Fadnes, Lars T.; Aas, Christer Frode; Vold, Jørn Henrik; Leiva, Rafael Alexander Mo; Ohldieck, Christian & Chalabianloo, Fatemeh [Show all 13 contributors for this article] (2021). Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV). PLoS Medicine. ISSN 1549-1277. 18(6). doi: 10.1371/journal.pmed.1003653. Full text in Research Archive
  • Midgard, Håvard; Ulstein, Kjersti Anne; Backe, Øystein; Foshaug, Tarjei; Sørli, Hanne & Vennesland, Kristin [Show all 11 contributors for this article] (2021). Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program in Oslo, Norway. International journal of drug policy. ISSN 0955-3959. 96. doi: 10.1016/j.drugpo.2021.103165.
  • Lyngbakken, Magnus; Berdal, Jan Erik; Eskesen, Arne N; Kvale, Dag; Olsen, Inge Christoffer & Rueegg, Corina Silvia [Show all 11 contributors for this article] (2020). A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics. Nature Communications. ISSN 2041-1723. 11:5284, p. 1–6. doi: 10.1038/s41467-020-19056-6. Full text in Research Archive
  • Hajarizadeh, Behzad; Cunningham, Evan B.; Valerio, Heather; Martinello, Marianne; Law, Matthew & Janjua, Naveed Z. [Show all 13 contributors for this article] (2020). Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. Journal of Hepatology. ISSN 0168-8278. 72(4), p. 643–657. doi: 10.1016/j.jhep.2019.11.012.
  • Artenie, Andreea A.; Cunningham, Evan B.; Dore, Gregory J.; Conway, Brian; Dalgard, Olav & Powis, Jeff [Show all 22 contributors for this article] (2020). Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study. Clinical Infectious Diseases. ISSN 1058-4838. 70(11), p. 2369–2376. doi: 10.1093/cid/ciz633.
  • Midgard, Håvard; Finbråten, Ane-Kristine; Malme, Kristian Nødtvedt; Berg-Pedersen, Riikka Mari; Tanum, Lars Håkon Reiestad & Inge Christoffer, Olsen [Show all 8 contributors for this article] (2020). Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs. Trials. ISSN 1745-6215. 21(1). doi: 10.1186/s13063-020-04434-8. Full text in Research Archive
  • Cunningham, Evan B.; Hajarizadeh, Behzad; Amin, Janaki; Litwin, Alain; Gane, Edward & Cooper, Curtis [Show all 22 contributors for this article] (2019). Adherence to once-daily and twice-daily direct-acting antiviral therapy for Hepatitis C infection among people with recent injection drug use or current opioid agonist therapy. Clinical Infectious Diseases. ISSN 1058-4838. 71(7), p. E115–E124. doi: 10.1093/cid/ciz1089.
  • Fadnes, Lars T.; Aas, Christer Frode; Vold, Jørn Henrik; Ohldieck, Christian; Leiva, Rafael Alexander Mo & Chalabianloo, Fatemeh [Show all 13 contributors for this article] (2019). Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV). BMC Infectious Diseases. ISSN 1471-2334. 19:943, p. 1–9. doi: 10.1186/s12879-019-4598-7. Full text in Research Archive
  • Gahrton, Caroline; Westman, Gabriel; Lindahl, Karin; Öhrn, Fredrik; Dalgard, Olav & Lidman, Christer [Show all 10 contributors for this article] (2019). Prevalence of Viremic hepatitis C, hepatitis B, and HIV infection, and vaccination status among prisoners in Stockholm County. BMC Infectious Diseases. ISSN 1471-2334. 19(1). doi: 10.1186/s12879-019-4581-3. Full text in Research Archive
  • Gulati, Rachna Shridhar; Wimalanathan, Thakshani; Andersen, Solveig Norheim; Isaksen, Kjetil; Lagging, Martin & Midgard, Håvard [Show all 8 contributors for this article] (2019). The relationship between IFNL4 genotype and the rate of fibrosis in hepatitis C patients. Scandinavian Journal of Gastroenterology. ISSN 0036-5521. 54(9), p. 1172–1175. doi: 10.1080/00365521.2019.1643403.
  • Safreed-Harmon, Kelly; Blach, Sarah; Aleman, Soo; Bollerup, Signe; Cooke, Graham & Dalgard, Olav [Show all 17 contributors for this article] (2019). The Consensus Hepatitis C Cascade of Care: standardized reporting to monitor progress toward elimination. Clinical Infectious Diseases. ISSN 1058-4838. 69(12), p. 2218–2227. doi: 10.1093/cid/ciz714.
  • Grebely, Jason; Dalgard, Olav; Conway, Brian; Cunningham, Evan B.; Bruggmann, Philip & Hajarizadeh, Behzad [Show all 31 contributors for this article] (2018). Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. The Lancet Gastroenterology and Hepatology. ISSN 2468-1253. 3(3), p. 153–161. doi: 10.1016/S2468-1253%2817%2930404-1.
  • Safreed-Harmon, Kelly; Hetherington, Kristina L.; Aleman, Soo; Alho, Hannu; Dalgard, Olav & Frisch, Tove [Show all 9 contributors for this article] (2018). Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study. PLOS ONE. ISSN 1932-6203. 13(1). doi: 10.1371/journal.pone.0190146.
  • Grebely, Jason; Conway, Brian; Cunningham, Evan B.; Fraser, Chris; Moriggia, Alberto & Gane, Edward [Show all 29 contributors for this article] (2018). Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. International journal of drug policy. ISSN 0955-3959. 62, p. 94–103. doi: 10.1016/j.drugpo.2018.10.004.
  • Cunningham, Evan B.; Amin, Janaki; Feld, Jordan J.; Bruneau, Julie; Dalgard, Olav & Powis, Jeff [Show all 28 contributors for this article] (2018). Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study. International journal of drug policy. ISSN 0955-3959. 62, p. 14–23. doi: 10.1016/j.drugpo.2018.08.013.
  • Day, Emma; Hellard, Margaret; Treloar, Carla; Bruneau, Julie; Martin, Natasha K. & Øvrehus, Anne [Show all 19 contributors for this article] (2018). Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. Liver international (Print). ISSN 1478-3223. p. 1–11. doi: 10.1111/liv.13949.
  • Wisløff, Torbjørn; White, Richard Aubrey; Dalgard, Olav; Amundsen, Ellen Johanna; Meijerink, Hinta & Kløvstad, Hilde (2018). Feasibility of reaching world health organization targets for hepatitis C and the cost‐effectiveness of alternative strategies. Journal of Viral Hepatitis. ISSN 1352-0504. 25(9), p. 1066–1077. doi: 10.1111/jvh.12904. Full text in Research Archive
  • Fraser, Hannah; Martin, Natasha K.; Brummer-Korvenkontio, Henrikki; Carrieri, Patrizia; Dalgard, Olav & Dillon, John [Show all 23 contributors for this article] (2018). Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. Journal of Hepatology. ISSN 0168-8278. 68(3), p. 402–411. doi: 10.1016/j.jhep.2017.10.010. Full text in Research Archive
  • Wisløff, Torbjørn; White, Richard Aubrey; Dalgard, Olav; Amundsen, Ellen Johanna; Meijerink, Hinta & Løvlie, Astrid Louise [Show all 7 contributors for this article] (2018). Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway. PharmacoEconomics (Auckland). ISSN 1170-7690. 36(5), p. 591–601. doi: 10.1007/s40273-017-0604-3. Full text in Research Archive
  • Bjøro, Benedikte; Dalgard, Olav; Midgard, Håvard; Verbaan, Hans; Småstuen, Milada Cvancarova & Rustøen, Tone (2018). Increased hope following successful treatment for hepatitis C infection. Journal of Advanced Nursing. ISSN 0309-2402. 74(3), p. 724–733. doi: 10.1111/jan.13487.
  • Blach, sarah; zeuzem, stefan; Manns, Michael; Altraif, Ibrahim; Duberg, Ann-Sofi & Muljono, David H [Show all 59 contributors for this article] (2017). Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. The Lancet Gastroenterology and Hepatology. ISSN 2468-1253. doi: 10.1016/S2468-1253%2816%2930181-9.
  • Grebely, Jason; Bruneau, Julie; lazarus, jeffrey; Dalgard, Olav; Bruggmann, Philip & Treloar, Carla [Show all 28 contributors for this article] (2017). Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. International journal of drug policy. ISSN 0955-3959. 47, p. 51–60. doi: 10.1016/j.drugpo.2017.05.019.
  • Cunningham, Evan B.; Hajarizadeh, Behzad; Dalgard, Olav; Amin, Janaki; Hellard, Margaret & Foster, Graham R. [Show all 48 contributors for this article] (2017). Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study. BMC Infectious Diseases. ISSN 1471-2334. 17(1). doi: 10.1186/s12879-017-2517-3.
  • Grebely, Jason; Dalgard, Olav; Cunningham, Evan B.; Hajarizadeh, Behzad; Foster, Graham R. & Bruggmann, Philip [Show all 23 contributors for this article] (2017). Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study. International journal of drug policy. ISSN 0955-3959. 47, p. 177–186. doi: 10.1016/j.drugpo.2017.05.020.
  • Midgard, Håvard; Hajarizadeh, Behzad; Cunningham, Evan B.; Conway, Brian; Backmund, Markus & Bruggmann, Philip [Show all 20 contributors for this article] (2017). Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study. International journal of drug policy. ISSN 0955-3959. 47, p. 230–238. doi: 10.1016/j.drugpo.2017.05.040.
  • Dalgard, Olav; Weiland, Ola; Noraberg, Geir; Karlsen, Lars Normann; Heggelund, Lars & Färkkilä, Martti [Show all 17 contributors for this article] (2017). Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections - A Scandinavian real-life study. PLOS ONE. ISSN 1932-6203. 12:e0179764(7), p. 1–8. doi: 10.1371/journal.pone.0179764.
  • Lamoury, François M.J.; Soker, Angelica; Martinez, Danica; Hajarizadeh, Behzad; Cunningham, Evan B. & Cunningham, Philip [Show all 18 contributors for this article] (2017). Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse. Journal of Clinical Virology. ISSN 1386-6532. 92, p. 32–38. doi: 10.1016/j.jcv.2017.05.007.
  • Meijerink, Hinta; White, Richard; Løvlie, Astrid Louise; De Blasio, Birgitte Freiesleben; Dalgard, Olav & Amundsen, Ellen Johanna [Show all 8 contributors for this article] (2017). Modelling the burden of hepatitis C infection among people who inject drugs in Norway, 1973–2030. BMC Infectious Diseases. ISSN 1471-2334. 17. doi: 10.1186/s12879-017-2631-2. Full text in Research Archive
  • Midgard, Håvard; Weir, Amanda; Palmateer, Nora; Lo Ve 3rd, Vincent; Pineda, Juan A. & Macias, Juan [Show all 7 contributors for this article] (2016). HCV epidemiology in high-risk groups and the risk of reinfection. Journal of Hepatology. ISSN 0168-8278. 1 Suppl , p. 33–45. doi: 10.1016/j.jhep.2016.07.012.
  • Midgard, Håvard; Bramness, Jørgen Gustav; Skurtveit, Svetlana; Haukeland, John Willy & Dalgard, Olav (2016). Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study. PLOS ONE. ISSN 1932-6203. 11(11). doi: 10.1371/journal.pone.0166451. Full text in Research Archive
  • Dore, Gregory J.; Altice, Frederick; Litwin, Alain H; Dalgard, Olav; Gane, Edward J. & Shibolet, Oren [Show all 22 contributors for this article] (2016). Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy a randomized trial. Annals of Internal Medicine. ISSN 0003-4819. 165(9), p. 625–634. doi: 10.7326/M16-0816.
  • Waldenström, Jesper; Westin, Johan; Nyström, Kristina; Christensen, Peer; Dalgard, Olav & Färkkilä, Martti [Show all 14 contributors for this article] (2016). Randomized trial evaluating the impact of ribavirin mono-therapy and double dosing on viral kinetics, ribavirin pharmacokinetics and anemia in hepatitis C virus genotype 1 infection. PLOS ONE. ISSN 1932-6203. 11(5). doi: 10.1371/journal.pone.0155142.
  • Dore, Gregory J.; Conway, Brian; Luo, Yan; Janczewska, Ewa; Knysz, Brygida & Liu, Yan [Show all 26 contributors for this article] (2016). Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials. Journal of Hepatology. ISSN 0168-8278. 64(1), p. 19–28. doi: 10.1016/j.jhep.2015.08.015.
  • Midgard, Håvard; Bjøro, Benedikte; Mæland, Arild; Zbigniew, Konopski; Kileng, Hege & Damås, Jan Kristian [Show all 15 contributors for this article] (2016). Hepatitis C reinfection after sustained virological response. Journal of Hepatology. ISSN 0168-8278. 64(5), p. 1020–1026. doi: 10.1016/j.jhep.2016.01.001.
  • Isaksen, Kjetil; Aabakken, Lars; Grimstad, Tore; Karlsen, Lars Normann; Sandvei, Per & Dalgard, Olav (2015). Hepatitt C-behandling ved tre norske sykehus 2000–11. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 135(22), p. 2052–2058. doi: 10.4045/tidsskr.14.1478.
  • Dalgard, Olav; Martinot-Peignoux, Michelle; Verbaan, Hans; Bjøro, Kristian; Ring-Larsen, Helmer & Marcellin, Patrick (2015). The usefulness of defining rapid virological response by a very sensitive assay (TMA) during treatment of HCV genotype 2/3 infection. PLOS ONE. ISSN 1932-6203. 10(8). doi: 10.1371/journal.pone.0120866.
  • Hatzakis, Angelos; Chulanov, V; Gadano, AC; Bergin, C; Ben-Ari, Z & Mossong, J [Show all 94 contributors for this article] (2015). The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - Volume 2. Journal of Viral Hepatitis. ISSN 1352-0504. 22(1), p. 26–45. doi: 10.1111/jvh.12351.
  • Gane, Edward J.; Kershenobich, D; Seguin-Devaux, C; Kristian, P; Aho, I & Dalgard, Olav [Show all 94 contributors for this article] (2015). Strategies to manage hepatitis C virus (HCV) infection disease burden - Volume 2. Journal of Viral Hepatitis. ISSN 1352-0504. 22(1), p. 46–73. doi: 10.1111/jvh.12352.
  • Saraswat, Vivek Anand; Norris, S; De Knegt, RJ; Sanchez Avila, JF; Sonderup, M & Zuckerman, E [Show all 94 contributors for this article] (2015). Historical epidemiology of hepatitis C virus (HCV) in select countries - Volume 2. Journal of Viral Hepatitis. ISSN 1352-0504. 22(1), p. 6–25. doi: 10.1111/jvh.12350.
  • Kielland, Knut Boe; Amundsen, Ellen Johanna & Dalgard, Olav (2014). HCV treatment uptake in people who have injected drugs — observations in a large cohort that received addiction treatment 1970–1984. Scandinavian Journal of Gastroenterology. ISSN 0036-5521. 49(12), p. 1465–1472. doi: 10.3109/00365521.2014.968860.
  • Kielland, Knut Boe; Delaveris, Gerd Jorunn Møller; Rogde, Sidsel; Eide, Tor Jacob; Amundsen, Ellen Johanna & Dalgard, Olav (2014). Liver fibrosis progression at autopsy in injecting drug users infected by hepatitis C: A longitudinal long-term cohort study. Journal of Hepatology. ISSN 0168-8278. 60(2), p. 260–266. doi: 10.1016/j.jhep.2013.09.022. Full text in Research Archive
  • Lagging, Martin; Rembeck, Karolina; Buhl, Mads Rauning; Christensen, Peer Brehm; Dalgard, Olav & Färkkilä, Martti [Show all 11 contributors for this article] (2013). Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse. Scandinavian Journal of Gastroenterology. ISSN 0036-5521. 48(7), p. 839–847. doi: 10.3109/00365521.2013.793389.
  • Robaeys, Geert; Grebely, Jason; Mauss, Stefan; Bruggmann, Philip; Moussalli, Joseph & De Gottardi, Andrea [Show all 17 contributors for this article] (2013). Recommendations for the Management of Hepatitis C Virus Infection Among People Who Inject Drugs. Clinical Infectious Diseases. ISSN 1058-4838. 57, p. S129–S137. doi: 10.1093/cid/cit302.
  • Grady, Bart P.; Schinkel, Janke; Thomas, Xiomara V. & Dalgard, Olav (2013). Hepatitis C Virus Reinfection Following Treatment Among People Who Use Drugs. Clinical Infectious Diseases. ISSN 1058-4838. 57, p. S105–S110. doi: 10.1093/cid/cit301.
  • Kielland, Knut Boe; Skaug, Kjell; Amundsen, Ellen Johanna & Dalgard, Olav (2013). All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study. Journal of Hepatology. ISSN 0168-8278. 58(1), p. 31–37. doi: 10.1016/j.jhep.2012.08.024.
  • Eskesen, Arne N; Melum, Espen; Moghaddam, Amir; Bjøro, Kristian; Verbaan, Hans & Ring-Larsen, Helmer [Show all 7 contributors for this article] (2012). Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort. European Journal of Gastroenterology and Hepathology. ISSN 0954-691X. 24(8), p. 890–896. doi: 10.1097/MEG.0b013e3283546efd.
  • Béziat, Vivien; Dalgard, Olav; Asselah, Tarik; Halfon, Philippe; Bedossa, Pierre & Boudifa, Ali [Show all 14 contributors for this article] (2012). CMV drives clonal expansion of NKG2C(+) NK cells expressing self-specific KIRs in chronic hepatitis patients. European Journal of Immunology. ISSN 0014-2980. 42(2), p. 447–457. doi: 10.1002/eji.201141826.
  • Sulkowski, Mark S.; Cooper, Curtis; Hunyady, Bela; Jia, Jidong; Ogurtsov, Pavel & Peck-Radosavljevic, Markus [Show all 9 contributors for this article] (2011). Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nature reviews: Gastroenterology & hepatology. ISSN 1759-5045. 8(4), p. 212–223. doi: 10.1038/nrgastro.2011.21.
  • Moghaddam, Amir; Melum, Espen; Reinton, Nils; Ring-Larsen, Helmer; Verbaan, Hans & Bjøro, Kristian [Show all 7 contributors for this article] (2011). IL28B Genetic Variation and Treatment Response in Patients with Hepatitis C Virus Genotype 3 Infection. Hepatology. ISSN 0270-9139. 53(3), p. 746–754. doi: 10.1002/hep.24154.
  • Midgard, Håvard; Bang, Christina; Raknerud, Nils & Dalgard, Olav (2010). Liver fibrosis in hepatitis C patients of Pakistani versus Scandinavian origin. Scandinavian Journal of Gastroenterology. ISSN 0036-5521. 45(12), p. 1503–1508. doi: 10.3109/00365521.2010.510571.
  • Mangia, Alessandra; Dalgard, Olav; Minerva, Nicola; Verbaan, Hans; Bacca, David A. & Ring-Larsen, Helmer [Show all 12 contributors for this article] (2010). Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin. Alimentary Pharmacology and Therapeutics. ISSN 0269-2813. 31(12), p. 1346–1353. doi: 10.1111/j.1365-2036.2010.04290.x.
  • Dalgard, Olav; Bjøro, Kristian; Ring-Larsen, H. & Verbaan, H (2010). In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks. Pooled analysis of two Scandinavian trials. European Journal of Gastroenterology and Hepathology. ISSN 0954-691X. 22(5), p. 552–556. doi: 10.1097/MEG.0b013e328335b29e.
  • Björnsson, Einar; Verbaan, Hans; Oksanen, Antti; Frydén, Aril; Johansson, Jonas & Friberg, Sarah [Show all 8 contributors for this article] (2009). Health-related quality of life in patients with different stages of liver disease induced by hepatitis C. Scandinavian Journal of Gastroenterology. ISSN 0036-5521. 44(7), p. 878–887. doi: 10.1080/00365520902898135.
  • Dalgard, Olav; Bjoro, K; Ring-Larsen, H; Bjornsson, E; Holberg-Petersen, M & Skovlund, Eva [Show all 14 contributors for this article] (2008). Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology. ISSN 0270-9139. 47, p. 35–42. doi: 10.1002/hep.21975.
  • Dalgard, Olav; Bjøro, T.; Hellum, K; Myrvang, Bjørn; Ritland, S & Skaug, Kjell [Show all 8 contributors for this article] (2004). Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study. Hepatology. ISSN 0270-9139. 40(6), p. 1260–65.
  • Dalgard, Olav; Egeland, Atle; Skaug, Kjell; Vilimas, Kostas & Steen, Tore (2004). Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection. Hepatology. ISSN 0270-9139. 39(1), p. 74–80.
  • Casey, P; Birbeck, G; McDonagh, C; Horgan, A; Dowrick, C & Dalgard, Olav [Show all 13 contributors for this article] (2004). Personality disorder, depression and functioning: results from the ODIN study. Journal of Affective Disorders. ISSN 0165-0327. 82, p. 277–283.
  • Dalgard, Olav; Jeansson, Stig Leo; Skaug, Kjell; Raknerud, Nils & Bell, Helge (2003). Hepatitis C in the general adult population of Oslo: prevalence and clinical spectrum. Scandinavian Journal of Gastroenterology. ISSN 0036-5521. 38(8), p. 864–70.
  • Dalgard, Olav; Bjøro, Kristian; Hellum, Kjell B.; Myrvang, Bjørn; Skaug, Kjell & Gutigard, Bjørg-Guri [Show all 7 contributors for this article] (2002). Treatment of chronic hepatitis C in injecting drug users: 5 years follow-up. European Addiction Research. ISSN 1022-6877. 8, p. 45–49.
  • Dalgard, Olav; Bjøro, Kristian; Hellum, Kjell B.; Myrvang, Bjørn; Bjøro, Trine & Haug, Egil [Show all 7 contributors for this article] (2002). Thyroid dysfunction during treatment if chronic hepatitis C with interferon alpha: no association with either interferon dosage of efficacy of therapy. Journal of Internal Medicine. ISSN 0954-6820. 252, p. 400–406.
  • Bell, Helge; Dalgard, Olav; Bjøro, Kristian; Hellum, Kjell B. & Myrvang, Bjørn (2002). Treatment of chronic hepatitis C. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 122, p. 926–28.

View all works in Cristin

  • Axfors, Cathrine; Schmitt, Andreas M.; Janiaud, Perrine; van’t Hooft, Janneke; Abd-Elsalam, Sherief & Abdo, Ehab F. [Show all 94 contributors for this article] (2021). Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials (Nature Communications, (2021), 12, 1, (2349), 10.1038/s41467-021-22446-z). Nature Communications. ISSN 2041-1723. 12(1). doi: 10.1038/s41467-021-23559-1.
  • Hauge, Joakim; Kielland, Knut Boe; Jarnaess, E.; Midgard, Håvard & Dalgard, Olav (2021). The HEPRIS Study -Prevalence of Hepatitis C in Norwegian Prisons.
  • Lyngbakken, Magnus; Berdal, Jan Erik; Eskesen, Arne N; Kvale, Dag; Inge Christoffer, Olsen & Rangberg, Anbjørg [Show all 10 contributors for this article] (2020). Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial. Trials. ISSN 1745-6215. 21. doi: 10.1186/s13063-020-04420-0.
  • Midgard, Håvard; Kielland, Knut Boe & Dalgard, Olav (2018). Eliminasjon av hepatitt C er mulig. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 138(7), p. 630–633. doi: 10.4045/tidsskr.18.0099.
  • Grebely, Jason; Swan, Tracy; hickman, matthew; Bruneau, Julie; Bruggmann, Philip & Dalgard, Olav [Show all 9 contributors for this article] (2017). Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C. Journal of Hepatology. ISSN 0168-8278. 66(5), p. 1101–1103. doi: 10.1016/j.jhep.2016.12.028.
  • Razavi-Shearer, D; Dalgard, Olav; Midgard, Håvard; Razavi, H; Wüsthoff, Linda Elise & Kielland, Knut Boe (2016). Aggressive treatment of hepatitis C in People who inject drugs in Norway: an integral step to eradicate the infection in this population.
  • Hjerrild, Simon; Dalgard, Olav; Christensen, Peer Brehm & Leutscher, Peter (2015). Debilitating fatigue as a treatment indication in chronic hepatitis C. Journal of Hepatology. ISSN 0168-8278. 63(6), p. 1533–1533. doi: 10.1016/j.jhep.2015.08.003.
  • Kielland, Knut Boe; Amundsen, Ellen Johanna & Dalgard, Olav (2013). Treatment uptake of HCV-infection in a Norwegian cohort of people who inject drugs.
  • Kielland, Knut Boe; Delaveris, Gerd Jorunn Møller; Rogde, Sidsel; Amundsen, Ellen Johanna; Eide, Tor Jacob & Dalgard, Olav (2013). Liver fibrosis among people who inject drugs exposed to hepatitis C, assessed through examination of liver tissue from autopsies.
  • Kielland, Knut Boe & Dalgard, Olav (2012). Mortality related to hepatitis B in injecting drug users. Hepatology. ISSN 0270-9139. 56(Supp. 1), p. 365A–366A.
  • Holter, Jan Cato; Dalgard, Olav; Haukeland, John Willy; Hansen, Mona; Yndestad, Arne & Zbigniew, Konopski [Show all 9 contributors for this article] (2012). Successful gene expression profiling in formalin-fixed and paraffin-embedded liver tissue from patients with chronic hepatitis C. Hepatology. ISSN 0270-9139. 56, p. 802A–802A.
  • Holter, Jan C.; Dalgard, Olav; Haukeland, John Willy; Hansen, Mona; Yndestad, Arne & Zbigniew, Konopski [Show all 9 contributors for this article] (2012). Successful gene expression profiling in formalin-fixed and paraffin-embedded liver tissue from patients with chronic hepatitis C. Hepatology. ISSN 0270-9139. 56(4).
  • Rembeck, Karolina; Norkrans, Gunnar P.; Dalgard, Olav; Langeland, Nina; Christensen, Peer B. & Buhl, Mads Rauning [Show all 9 contributors for this article] (2011). The efficiency of re-treatment with peg-interferon and ribavirin in patients with chronic hepatitis C infection genotype 2 or 3 with prior relapse. Hepatology. ISSN 0270-9139. 54, p. 1002A–1003A.
  • Dalgard, Olav; Moghaddam, Amir; Verbaan, Hans; Ring-Larsen, Helmer; Bjøro, Kristian & Melum, Espen (2010). IL28B GENETIC VARIATION AND TREATMENT RESPONSE IN PATIENTS WITH HCV GENOTYPE 3 INFECTION. Hepatology. ISSN 0270-9139. 52(4), p. 751A–751A.
  • Dalgard, Olav; Verbaan, H; Ring-Larsen, H & Bjøro, Kristian (2008). IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION AND RVR 14 WEEKS TREATMENT IS NON-INFERIOR TO 24 WEEKS. POOLED ANALYSIS OF TWO SCANDINAVIAN TRIALS. Hepatology. ISSN 0270-9139. 48(4), p. 1148A–1148A.
  • Kielland, Knut Boe; Dalgard, Olav & Skaug, Kjell (2008). Mortality and end-stage liver disease related to hepatitis C in injecting drug users.
  • Dalgard, Olav; Bjøro, Kristian; Myrvang, Bjørn; Hellum, Kjell B.; Skaug, Kjell & Gutigard, Bjørg-Guri [Show all 7 contributors for this article] (2000). Long term follow-up after treatment of chronic hepatitis C with interferon-A. Reinfection in injecting drug users.
  • Dalgard, Olav; Bjøro, Kristian; Hellum, Kjell B.; Myrvang, Bjørn; Bjøro, Trine & Haug, Egil [Show all 8 contributors for this article] (2000). Thyroid dysfunction during treatment of chronic hepatitis C is associated with virological treatment response.
  • Dalgard, Olav; Hellum, Kjell B.; Bjøro, Kristian; Langtind, J.; Ritland, Ståle & Sundøy, A. [Show all 8 contributors for this article] (1999). Thyreoideasykdom ved behandling av kronisk hepatitt C med Interferon alfa.
  • Dalgard, Olav; Hellum, Kjell B.; Bjøro, Kristian; Myrvang, Bjørn; Bjøro, Trine & Haug, Egil [Show all 7 contributors for this article] (1999). Thyreoideasykdom ved behandling av kronisk hepatitt C med Interferon Alfa.
  • Litleskare, Irene; Bragstad, Karoline; Kran, Anne-Marte Bakken; Kanestrøm, Anita; Stene-Johansen, Kathrine & Kro, Grete Birkeland [Show all 10 contributors for this article] (2018). Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2017. Norwegian Institute of Public Health, Department for Infectious disease registries . ISSN 978-82-8082-973-3. Full text in Research Archive
  • Dalgard, Olav (2004). Hepatitis C virus infection in Oslo: Prevalence, clinical spectrum and treatment issues. Det medisinske fakultet, Universitetet i Oslo. ISSN 82-8080-095-6.

View all works in Cristin

Published June 6, 2014 2:25 PM - Last modified May 26, 2015 10:24 AM